Canaccord Drug & Device ConferenceGary Phillips, CEOOctober 13th20262FORWARD LOOKING STATEMENT This document contains forward-looking statements, including statements concerning Syntara’s future financial position, plans, and the potential of its products and product candidates, which are based...
Investor Presentation Canaccord Drug & Device Conference
Filed with ASX · · 20 pages · English
Release
In the deck
Earlier from Syntara
- Further significant results from SNT-4728 iRBD Phase 2 trial
- Notification regarding unquoted securities - SNT
- Syntara expands SNT-9465 skin scarring study
- Syntara receives A$4.7m R&D Tax Incentive
- Application for quotation of securities - SNT
Later from Syntara
All Syntara news releasesFollow Syntara into a list and get an email when it puts out news.
Follow Syntara